• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?

作者信息

Lure Allison C, Sánchez Pablo J, Slaughter Jonathan L

机构信息

Department of Pediatrics, Division of Neonatology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, USA.

Department of Pediatrics, Division of Infectious Disease, Nationwide Children's Hospital, Columbus, OH, USA.

出版信息

J Perinatol. 2024 Jan;44(1):142-145. doi: 10.1038/s41372-023-01769-3. Epub 2023 Sep 9.

DOI:10.1038/s41372-023-01769-3
PMID:37689809
Abstract
摘要

相似文献

1
Does prefusion F protein-based respiratory syncytial virus immunization in pregnancy safely promote transplacental transfer of neutralizing antibodies?孕期基于融合前F蛋白的呼吸道合胞病毒免疫能否安全促进中和抗体的胎盘转运？
J Perinatol. 2024 Jan;44(1):142-145. doi: 10.1038/s41372-023-01769-3. Epub 2023 Sep 9.
2
Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.作为呼吸道合胞病毒的母体疫苗的替代病毒样颗粒相关前融合 F 蛋白。
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00914-19. Print 2019 Dec 1.
3
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.孕期融合前 F 蛋白为基础的呼吸道合胞病毒免疫接种。
N Engl J Med. 2022 Apr 28;386(17):1615-1626. doi: 10.1056/NEJMoa2106062.
4
A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.副流感病毒载体表达呼吸道合胞病毒（RSV）融合前 F 蛋白比 RSV 更有效地增强 RSV 初次免疫。
J Virol. 2020 Dec 22;95(2). doi: 10.1128/JVI.01512-20.
5
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.呼吸道合胞病毒F糖蛋白构象对诱导保护性免疫反应的影响
J Virol. 2016 May 12;90(11):5485-5498. doi: 10.1128/JVI.00338-16. Print 2016 Jun 1.
6
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.候选疫苗表达的呼吸道合胞病毒预融合F蛋白诱导的中和抗体反应增强
J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.
7
Clinical Potential of Prefusion RSV F-specific Antibodies.融合前 RSV F 特异性抗体的临床潜力。
Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17.
8
Preventative therapies for respiratory Syncytial virus (RSV) in children: Where are we now?预防儿童呼吸道合胞病毒（RSV）的疗法：我们现在在哪里？
Paediatr Respir Rev. 2024 Mar;49:24-27. doi: 10.1016/j.prrv.2023.08.005. Epub 2023 Aug 29.
9
Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine.用于呼吸道合胞病毒疫苗的高免疫原性预融合稳定F糖蛋白抗原的合理设计。
Sci Transl Med. 2023 Apr 26;15(693):eade6422. doi: 10.1126/scitranslmed.ade6422.
10
Passive Immunization Strategies to Prevent Severe Respiratory Syncytial Virus Infection Among Newborns and Young Infants.预防新生儿和婴幼儿严重呼吸道合胞病毒感染的被动免疫策略。
J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S110-S114. doi: 10.1093/jpids/piae058.

引用本文的文献

1
RSVpreF vaccination in pregnancy: a meta-analysis of maternal-fetal safety and infant efficacy.孕期接种呼吸道合胞病毒融合前体蛋白疫苗：母婴安全性及婴儿有效性的荟萃分析
Obstet Gynecol Sci. 2024 Nov;67(6):511-524. doi: 10.5468/ogs.24213. Epub 2024 Sep 27.

本文引用的文献

1
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.孕期接种二价融合前F疫苗预防婴儿呼吸道合胞病毒疾病
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
2
Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.孕期融合前 F 蛋白为基础的呼吸道合胞病毒免疫接种。
N Engl J Med. 2022 Apr 28;386(17):1615-1626. doi: 10.1056/NEJMoa2106062.
3
Do we need to adjust for interim analyses in a Bayesian adaptive trial design?在贝叶斯自适应试验设计中，我们是否需要针对中期分析进行调整？
BMC Med Res Methodol. 2020 Jun 10;20(1):150. doi: 10.1186/s12874-020-01042-7.
4
Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.贝叶斯预测概率在单臂II期试验中期无效性分析中的应用。
Transl Cancer Res. 2019 Jul;8(Suppl 4):S404-S420. doi: 10.21037/tcr.2019.05.17.
5
Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.评估帕利珠单抗预防早产儿呼吸道合胞病毒感染的成本差异。
Pharmacoecon Open. 2018 Mar;2(1):53-61. doi: 10.1007/s41669-017-0042-3.
6
Interim analysis: A rational approach of decision making in clinical trial.中期分析：临床试验中一种合理的决策方法。
J Adv Pharm Technol Res. 2016 Oct-Dec;7(4):118-122. doi: 10.4103/2231-4040.191414.
7
Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.用于预防和治疗呼吸道合胞病毒感染的新型抗体的研发及临床应用
Vaccine. 2017 Jan 11;35(3):496-502. doi: 10.1016/j.vaccine.2016.09.026. Epub 2016 Sep 28.
8
Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.贝叶斯监测方法在决定是否以及何时停止临床试验中的优势：以新生儿低温治疗试验为例
Trials. 2016 Jul 22;17(1):335. doi: 10.1186/s13063-016-1480-4.
9
Stopping guidelines for an effectiveness trial: what should the protocol specify?有效性试验的停止准则：方案应规定哪些内容？
Trials. 2016 May 10;17(1):240. doi: 10.1186/s13063-016-1367-4.
10
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.莫他珠单抗预防健康美洲原住民婴儿呼吸道合胞病毒病的疗效：一项 3 期随机双盲安慰剂对照试验。
Lancet Infect Dis. 2015 Dec;15(12):1398-408. doi: 10.1016/S1473-3099(15)00247-9. Epub 2015 Nov 4.